Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Nuwellis Announces First Patient Treated With Newly Launched QUELIMMUNE Therapy At Cincinnati Children's

Author: Benzinga Newsdesk | July 26, 2024 09:01am

QUELIMMUNE, Manufactured For SeaStar Medical And Licensed By Nuwellis, Targets Pediatric AKI Patients With Sepsis Requiring Kidney Replacement Therapy

Posted In: ICU NUWE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist